Gene diversity can alter metabolic individuality
09 September 2016
A new Japanese study of the effects of environmental and genetic influences on individual differences in proteomics and metabolomics has identified biomarkers for early disease prevention and diagnosis, through the identification and quantification of blood metabolites.
The next breakthrough? MSK’s Sadelain ties up with Fate on off-the-shelf CAR-Ts
08 September 2016
Fate Therapeutics is teaming up with one of the star scientists at Memorial Sloan Kettering to start work on off-the-shelf T cell therapies, one of the hottest fields in the next-gen CAR-T field.
NCI embraces scientific road map to achieve Cancer Moonshot goals
08 September 2016
National Cancer Institute (NCI) Acting Director Douglas Lowy, M.D., today accepted the recommendations of a Blue Ribbon Panel (BRP) on 10 scientific approaches most likely to make a decade’s worth of progress against cancer in five years under the Cancer Moonshot. The report was presented by the BRP to the National Cancer Advisory Board (NCAB), and it was subsequently considered and accepted by the NCAB with revisions that reflect the NCAB’s discussion. An overview of the report was published today in the journal Science.
Repositive adds data sets, search capabilities to online genomic research platform
08 September 2016
Repositive has introduced the full version of its online genomics data platform. The latest version gives users access to 992,000 data sets, 23 times as many as were available previously, plus search functions designed to make it easier for researchers to identify the specific data they need.
07 September 2016
Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced that Laurent Fischer, M.D., the company’s chief executive officer, has been appointed to serve on the Liver Forum’s steering committee. The steering committee provides overall scientific leadership to the Liver Forum. The goal of the Liver Forum is to leverage the scientific community’s collective knowledge and experience with therapies to facilitate drug development for the treatment of liver disease.
Pfizer goes local with Russian joint venture
07 September 2016
In July 2016, the U.S. pharmaceutical giant Pfizer became the first foreign company in its sector to localize its business in Russia with a Russian partner. Pfizer and the Russian-American company NovaMedica, whose shareholders include the Russian state-owned company Rusnano, decided to jointly invest in the construction of a plant in the Kaluga Region, 125 miles southwest of Moscow.
The 10 most active VCs in healthcare
07 September 2016
These past couple of weeks have seen more than a handful of massive healthcare deals. Moderna Therapeutics secured $451 million toward a planned $600 million round, Denali Therapeutics disclosed a $130 million Series B, Arcus Biosciences raised $70 million and ClearCare announced a $60 million growth financing. While tech gets the most media play, healthcare keeps chugging along.
Belgian researchers say AI could improve accuracy of diagnosing lung disease
07 September 2016
Researchers at the University of Leuven in Belgium said a study they conducted showed artificial intelligence could help interpret, and thereby improve, lung function tests used to diagnose long-term lung disease.
Benefits for international multicenter clinical trials in Russia
07 September 2016
In the last 20 years, Russia has seen an increasing growth of the clinical trials industry. Among the factors contributing to that are topgrade research facilities, vast and easy-to-access populations and low participation costs. Over the past two years, significant changes have occurred in this market that are likely to have a global impact. All recent legislative efforts were aimed at harmonizing the local regulatory requirements with international standards and pharmacovigilance procedures. Clinical trials in Russia undergo regular FDA inspections and are among one of the world’s best in terms of quality, exceeding Western countries.
New “shape memory” exoskeleton underway in Voronezh
06 September 2016
Andrei Sinegub, a 21-year-old inventor in Voronezh, in Central Russia, is developing a new exoskeleton based on nitinol, a shape memory alloy of nickel and titanium said to possess very useful properties, 3dtoday.ru reported.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024